Remofuscin-mediated lipofuscin removal from RPE cells
PrimaryKatairo's central causal theory is that accumulated lipofuscin in retinal pigment epithelium cells contributes to seriously disabling retinal diseases, and that Remofuscin can remove or reduce lipofuscin from living RPE cells. If this mechanism is correct, treatment should lower retinal autofluorescence signals associated with lipofuscin burden and should slow or improve disease-related visual dysfunction in Stargardt disease and dry age-related macular degeneration. Testable predictions include reduced qAF8 or related autofluorescence measures after treatment, preservation or improvement of visual function measures such as BCVA, low-luminance visual acuity, microperimetry, reading speed, and patient-reported visual function, and structural stabilization on retinal imaging such as SD-OCT.
Popperian evaluation
The premise is credible but still carrying real biological risk. Lipofuscin accumulation in RPE cells is a plausible contributor to Stargardt disease and dry age-related macular degeneration, and qAF8 gives the theory a measurable mechanistic readout. The thinner part is the drug claim: the supplied evidence shows that Remofuscin was tested against this mechanism, but it does not show that Remofuscin has already removed lipofuscin from living human RPE cells.
Supporting evidence: The theory links accumulated RPE lipofuscin to disabling retinal disease, including Stargardt disease and dry age-related macular degeneration.; STARTT enrolled 87 genetically confirmed Stargardt disease patients in a double-masked, placebo-controlled proof-of-concept trial of 20 mg oral Remofuscin for 24 months.; Baseline STARTT patients had high qAF8 values, with median qAF8 of 438 units and range 210 to 729.
Counter evidence: The evidence provided does not include a completed efficacy result showing that Remofuscin reduced lipofuscin in living human RPE cells.; qAF8 is treated as a proxy for lipofuscin burden, but the evidence explicitly flags measurement variability and the need to control it.
The theory explains why qAF8 should fall before, or alongside, visual benefit: if the drug clears lipofuscin, autofluorescence should drop. That is a clean mechanistic chain. But the current evidence is mostly trial design and endpoint validation, not outcome evidence. Without post-treatment qAF8, BCVA, microperimetry, reading speed, or SD-OCT results, we cannot say the theory explains observed clinical change better than disease fluctuation, imaging noise, selection effects, or slower natural progression.
Supporting evidence: The STARTT primary endpoint was change in mean qAF8, directly matching the theory's mechanistic prediction.; STARTT also tracked BCVA, LLVA, mesopic microperimetry, SD-OCT, reading speed, NEI VFQ-25, and Functional Reading Independence Index.; The qAF repeatability study found intra-visit ICC values of 0.88 to 0.96, so the endpoint can track signal when variability is handled carefully.
Counter evidence: No treatment outcome data are supplied showing that qAF8 decreased after Remofuscin.; Inter-visit qAF repeatability was weaker, with plus or minus 40.5% repeatability and overall ICC of 0.76, which leaves room for noise to imitate change.; No evidence here shows that visual function improved after lipofuscin reduction, so the clinical causal link remains unproven in this dossier.
This theory is highly falsifiable. It predicts a measurable fall in qAF8 or related autofluorescence after treatment, plus preservation or improvement in visual function and structural retinal measures. A randomized, placebo-controlled, 24-month trial can make the theory look wrong in several clear ways: no qAF8 reduction, qAF8 reduction without functional benefit, worsening SD-OCT structure, or no difference versus placebo.
Supporting evidence: The theory predicts reduced qAF8 or related quantitative autofluorescence measures after treatment.; STARTT used change in mean qAF8 as its primary outcome.; Secondary endpoints included BCVA, LLVA, mesopic microperimetry, SD-OCT, reading speed, NEI VFQ-25, and Functional Reading Independence Index.; The trial was double-masked and placebo-controlled, which gives negative results real Popperian force.
Counter evidence: qAF variability is large between visits, with plus or minus 40.5% inter-visit repeatability, so small claimed effects would be hard to interpret.; The dry AMD extension of the theory is less tightly supported by the supplied trial evidence, which centers on genetically confirmed Stargardt disease.
Reasoning tree
Public endorsements
The provided public evidence only places Dr. Mario Fsadni on Katairo's team page as Acting Medical Director. It does not include any quote, publication, or attributed statement from him about Remofuscin, lipofuscin removal, retinal autofluorescence, or the related disease claims. On this record, he is publicly silent on the theory.
Schraermeyer publicly aligns with the theory. He is cited as holding a patent for removing lipofuscin from the retinal pigment epithelium, is disclosed as a Katairo shareholder, and appears as inventor on a Katairo patent application for treating lipofuscin-associated disease. That is stronger than a passing mention, even if the dossier does not include a direct personal quote from him about Remofuscin.
Evidence publication IDs: eb56177c-f576-49c6-8d96-cc8ffec2bfb4, 5881f50c-9b62-449c-90ea-5361dff51a65
The provided public evidence ties Wolfgang Klein to finance and philanthropy, not to Katairo's retinal lipofuscin theory. The company materials describe Remofuscin removing lipofuscin from living RPE cells, but nothing here shows Klein endorsing, mentioning, or disputing that mechanism himself.